Schrdinger Receives Fast Track Designation for SGR-1505 for the
| SDGR Stock | USD 19.53 0.80 3.94% |
Slightly above 62% of Schrodinger's investor base is looking to short. The analysis of the overall investor sentiment regarding Schrodinger suggests that many traders are alarmed. Schrodinger's investing sentiment overview a quick insight into current market opportunities from investing in Schrodinger. Many technical investors use Schrodinger stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Schrodinger | Build AI portfolio with Schrodinger Stock |
Schrdinger receives FDA Fast Track designation for SGR-1505, targeting Waldenstrm macroglobulinemia. SGR-1505 shows promise in clinical trial
Read at gurufocus.com
 |
Schrodinger Fundamental Analysis
We analyze Schrodinger's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Schrodinger using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Schrodinger based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Schrodinger is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Schrodinger Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Schrodinger stock to make a market-neutral strategy. Peer analysis of Schrodinger could also be used in its relative valuation, which is a method of valuing Schrodinger by comparing valuation metrics with similar companies.
Peers
Schrodinger Related Equities
| TWST | Twist Bioscience | 0.33 | ||||
| CRSP | Crispr Therapeutics | 0.30 | ||||
| VEEV | Veeva Systems | 1.00 | ||||
| NTLA | Intellia Therapeutics | 1.29 | ||||
| GEHC | GE HealthCare | 2.06 | ||||
| TXG | 10X Genomics | 2.75 | ||||
| TDOC | Teladoc | 3.74 | ||||
| PGNY | Progyny | 4.34 | ||||
| BEAM | Beam Therapeutics | 4.46 |
Additional Tools for Schrodinger Stock Analysis
When running Schrodinger's price analysis, check to measure Schrodinger's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Schrodinger is operating at the current time. Most of Schrodinger's value examination focuses on studying past and present price action to predict the probability of Schrodinger's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Schrodinger's price. Additionally, you may evaluate how the addition of Schrodinger to your portfolios can decrease your overall portfolio volatility.